STAT3 and neoplasm: Notably, the authors claimed sorafenib negatively regulates the activation of STAT3, a transcription factor that we reported to be markedly elevated in the muscle of tumor hosts and directly involved in the pathogenesis of cancer-associated cachexia [25], thus also partially explaining the beneficial effects observed in tumor hosts.